Описание

Kaplan-Meier survival analysis plots the time to first exacerbation in Lertal-treated versus control children, showing a longer exacerbation-free interval in the nutraceutical group.

Figure 4

Chart

Source Paper

A polycentric, randomized, parallel-group, study on Lertal®, a multicomponent nutraceutical, as preventive treatment in children with allergic rhinoconjunctivitis: phase II.

Italian journal of pediatrics (2019)

PMID: 31319883

DOI: 10.1186/s13052-019-0678-y

Cite This Figure

![Figure 4: Kaplan-Meier survival analysis plots the time to first exacerbation in Lertal-treated versus control children, showing a longer exacerbation-free interval in the nutraceutical group.]()

> Source: Gianluigi Marseglia et al. "A polycentric, randomized, parallel-group, study on Lertal®, a multicomponent nu." *Italian journal of pediatrics*, 2019. PMID: [31319883](https://pubmed.ncbi.nlm.nih.gov/31319883/)

<figure>
  <img src="" alt="Kaplan-Meier survival analysis plots the time to first exacerbation in Lertal-treated versus control children, showing a longer exacerbation-free interval in the nutraceutical group." />
  <figcaption>Figure 4. Kaplan-Meier survival analysis plots the time to first exacerbation in Lertal-treated versus control children, showing a longer exacerbation-free interval in the nutraceutical group.<br>  Source: Gianluigi Marseglia et al. "A polycentric, randomized, parallel-group, study on Lertal®, a multicomponent nu." <em>Italian journal of pediatrics</em>, 2019. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31319883/">31319883</a></figcaption>
</figure>

Связанные доказательства

Quercetin для Allergic Rhinitis

Оценка C · 5 исследований